-transparent.png){kind=logo}
Malignant hypertension is a hypertensive emergency, with rapid disease progression and poor prognosis. Although recognized as a separate entity more than a century ago, significant knowledge gaps remain about its pathogenesis and treatment. This narrative review summarizes current viewpoints, research gaps, and challenges with a view to pooling future efforts at improving treatment and prognosis.
Related Publications
Romain Boulestreau, and
Bert-Jan H van den Born, and
Gregory Y H Lip, and
Ajay Gupta
August 2016,
Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese,
Romain Boulestreau, and
Bert-Jan H van den Born, and
Gregory Y H Lip, and
Ajay Gupta
May 1981,
American journal of hospital pharmacy,
Romain Boulestreau, and
Bert-Jan H van den Born, and
Gregory Y H Lip, and
Ajay Gupta
November 2013,
Nucleic acids research,
Romain Boulestreau, and
Bert-Jan H van den Born, and
Gregory Y H Lip, and
Ajay Gupta
January 2003,
Medicinski pregled,
Romain Boulestreau, and
Bert-Jan H van den Born, and
Gregory Y H Lip, and
Ajay Gupta
February 2018,
Drug discovery today,
Romain Boulestreau, and
Bert-Jan H van den Born, and
Gregory Y H Lip, and
Ajay Gupta
February 1991,
The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses,
Romain Boulestreau, and
Bert-Jan H van den Born, and
Gregory Y H Lip, and
Ajay Gupta
October 2021,
British journal of clinical pharmacology,
Romain Boulestreau, and
Bert-Jan H van den Born, and
Gregory Y H Lip, and
Ajay Gupta
November 2017,
JBJS reviews,
Romain Boulestreau, and
Bert-Jan H van den Born, and
Gregory Y H Lip, and
Ajay Gupta
February 2021,
Indian journal of ophthalmology,
Romain Boulestreau, and
Bert-Jan H van den Born, and
Gregory Y H Lip, and
Ajay Gupta
August 2021,
International journal of molecular sciences,
